The rise of tamoxifen: temporal and geographical trends of tamoxifen use in Ontario
- PMID: 9065597
- DOI: 10.1023/a:1005736325626
The rise of tamoxifen: temporal and geographical trends of tamoxifen use in Ontario
Abstract
Purpose: To describe the change in use of tamoxifen over time and across countries in Ontario.
Methods: Data from the Ontario Drug Benefit (ODB) plan, Census Canada, and the Ontario Cancer Registry (OCR) were combined and analysed to determine rates of tamoxifen use for females over 65 for each county and the province overall, by year. Rates were analyzed by repeated measures ANOVA to determine significance of changes over time. Consistency of tamoxifen use across counties was determined by the Spearman rank correlation coefficient, and overall variation between counties was described using three statistical techniques: Chi-square analysis, the extremal quotient (EQ), and the systematic component of variation (SCV).
Results: The number of one-month tamoxifen prescriptions per incident case of breast cancer rose significantly from 13.51 in 1985 to 20.54 in 1990 (p < 0.001) and to 34.06 in 1992 (p = 0.001). Viewed differently, the number of women over 65 receiving tamoxifen prescriptions per incident case of breast cancer changed from 1.91 in 1985 to 3.14 in 1990 to 4.54 in 1992. Statistically significant variation in the rate of tamoxifen prescribing was demonstrated between Ontario counties in all three years by Chi Squared analysis (p < 0.0001). Both the EQ and the SCV declined from 1985 to 1990, suggesting more uniform prescribing across the province. Little change in overall variation was seen between 1990 and 1992. All counties over time tended to prescribe generic preparations more often and shifted from 10 mg to 20 mg formulations.
Conclusions: The significant increase in the rate of tamoxifen use and trend towards more uniform prescribing across Ontario between 1985 and 1990 coincided with the publication of two important documents outlining the benefits of tamoxifen in early breast cancer. Despite this trend, variation in tamoxifen use between counties remains. There has been little change in uniformity of prescribing since 1990.
Similar articles
-
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.J Clin Pharm Ther. 2015 Feb;40(1):76-82. doi: 10.1111/jcpt.12227. Epub 2014 Nov 4. J Clin Pharm Ther. 2015. PMID: 25367863
-
The control of breast cancer: the role of tamoxifen.Semin Oncol. 1997 Feb;24(1 Suppl 1):S1-5-S1-19. Semin Oncol. 1997. PMID: 9045316 Review.
-
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62. doi: 10.1093/jnci/dji372. J Natl Cancer Inst. 2005. PMID: 16288118 Clinical Trial.
-
Endometrial and other primary cancers after tamoxifen treatment of breast cancer -- results of retrospective cohort study.Eur J Obstet Gynecol Reprod Biol. 2001 Mar;95(1):105-10. doi: 10.1016/s0301-2115(00)00376-6. Eur J Obstet Gynecol Reprod Biol. 2001. PMID: 11267730
-
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.Clin Ther. 2007 Aug;29(8):1535-47. doi: 10.1016/j.clinthera.2007.08.013. Clin Ther. 2007. PMID: 17919537 Review.
Cited by
-
Trends of uterine carcinosarcoma in the United States.J Gynecol Oncol. 2018 Mar;29(2):e22. doi: 10.3802/jgo.2018.29.e22. Epub 2018 Jan 5. J Gynecol Oncol. 2018. PMID: 29400015 Free PMC article.
-
Breast cancer survival by teaching status of the initial treating hospital.CMAJ. 2001 Jan 23;164(2):183-8. CMAJ. 2001. PMID: 11332310 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical